A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression

Bipolar Disorders

Volumn 19, Issue 3, 2017, Pages 198-213

  Soczynska, Joanna K ^a,b   Kennedy, Sidney H ^a,b,c   Alsuwaidan, Mohammad ^c,d   Mansur, Rodrigo B ^b   Li, Madeline ^b,c   McAndrews, Mary Pat ^b,c   Brietzke, Elisa ^e   Woldeyohannes, Hanna O ^b   Taylor, Valerie H ^c,f   McIntyre, Roger S ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KUWAIT UNIVERSITY   (Kuwait)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

bipolar disorder; clinical trial; cytokines; depression; inflammation; microglia; minocycline

Indexed keywords

CYTOKINE; EOTAXIN; EOTAXIN 3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23P40; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE FUNCTION TEST; CONTROLLED STUDY; CORPUSCULAR HAEMOGLOBIN CONCENTRATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE PARAMETERS; ESOPHAGUS SWELLING; EXECUTIVE FUNCTION; FACIAL SWELLING; FEMALE; FEVER; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPERPIGMENTATION; HYPOMANIA; IMMUNOASSAY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUTROPHIL COUNT; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; RASH; SIDE EFFECT; SWELLING; TREATMENT RESPONSE; URTICARIA; VERBAL MEMORY; BIPOLAR DISORDER; COGNITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHEMOKINE CCL26; COGNITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MIDDLE AGED; MINOCYCLINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 85020448330     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12496     Document Type: Article

References (141)

1. Munkholm K, Vinberg M, Vedel KL. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16-27.
2. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47:1119-1133.
3. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15-25.
4. Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry. 2015;76:142-150.
5. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014;42:93-115.
6. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696-1709.
7. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry. 2008;65:395-407.
8. Drexhage RC, Heul-Nieuwenhuijsen L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol. 2010;13:1369-1381.
9. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90:263-267.
10. McKernan DP, Dennison U, Gaszner G, Cryan JF, Dinan TG. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry. 2011;1:e36.
11. Barbosa IG, Rocha NP, Bauer ME, et al. Chemokines in bipolar disorder: trait or state? Eur Arch Psychiatry Clin Neurosci. 2013;263:159-165.
12. Brietzke E, Kauer-Sant'anna M, Teixeira AL, Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun. 2009;23:1079-1082.
13. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun. 2011;25:1206-1213.
14. Bai YM, Su TP, Li CT, et al. Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. Bipolar Disord. 2015;17:269-277.
15. Bai YM, Su TP, Tsai SJ, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 2014;166:187-192.
16. Jakobsson J, Bjerke M, Sahebi S, et al. Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. J Psychiatry Neurosci. 2015;40:250-258.
17. Djurovic S, Gustafsson O, Mattingsdal M, et al. A genome-wide association study of bipolar disorder in Norwegian individuals, followed by replication in Icelandic sample. J Affect Disord. 2010;126:312-316.
18. Brambilla P, Bellani M, Isola M, et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry. 2014;4:e406.
19. Magalhaes PV, Jansen K, Stertz L, et al. Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults. J Psychiatr Res. 2014;48:13-15.
20. Herberth M, Koethe D, Levin Y, et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics. 2011;11:94-105.
21. Kalelioglu T, Akkus M, Karamustafalioglu N, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as inflammation markers for bipolar disorder. Psychiatry Res. 2015;228:925-927.
22. Barbosa IG, Rocha NP, Assis F, et al. Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders. Int J Neuropsychopharmacol. 2015;18.
23. Knijff EM, Ruwhof C, de Wit HJ, et al. Monocyte-derived dendritic cells in bipolar disorder. Biol Psychiatry. 2006;59:317-326.
24. do Prado CH, Rizzo LB, Wieck A, et al. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology. 2013;38:667-676.
25. Wieck A, Grassi-Oliveira R, do Prado CH, et al. Differential neuroendocrine and immune responses to acute psychosocial stress in women with type 1 bipolar disorder. Brain Behav Immun. 2013;34:47-55.
26. Breunis MN, Kupka RW, Nolen WA, et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry. 2003;53:157-165.
27. Knijff EM, Breunis MN, van Geest MC, et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006;8:740-750.
28. Darko DF, Rose J, Gillin JC, Golshan S, Baird SM. Neutrophilia and lymphopenia in major mood disorders. Psychiatry Res. 1988;25:243-251.
29. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136:110-116.
30. Tsai SY, Chung KH, Huang SH, Chen PH, Lee HC, Kuo CJ. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disord. 2014;16:800-808.
31. Isgren A, Jakobsson J, Palsson E, et al. Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain Behav Immun. 2015;43:198-204.
32. Bayard-Burfield L, Alling C, Blennow K, Jonsson S, Traskman-Bendz L. Impairment of the blood-CSF barrier in suicide attempters. Eur Neuropsychopharmacol. 1996;6:195-199.
33. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res. 2010;44:321-330.
34. Maxeiner HG, Marion SE, Kurfiss ST, Brettschneider J, Tumani H, Bechter K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine. 2014;69:62-67.
35. Zetterberg H, Jakobsson J, Redsater M, et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res. 2014;217:143-146.
36. Haarman BC, Riemersma-Van der Lek RF, de Groot JC, et al. Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun. 2014;40:219-225.
37. Haarman BC, Burger H, Doorduin J, et al. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - a combined magnetic resonance imaging and positron emission tomography study. Brain Behav Immun. 2016;56:21-33.
38. Haarman BC, Burger H, Doorduin J, et al. Corrigendum to “Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder - A combined magnetic resonance imaging and positron emission tomography study” [Brain Behav. Immun. (2015)]. Brain Behav Immun. 2017;61:387-388.
39. Doganavsargil-Baysal O, Cinemre B, Aksoy UM, et al. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol. 2013;28:160-167.
40. Barbosa IG, Rocha NP, Huguet RB, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137:151-155.
41. Hoseth EZ, Westlye LT, Hope S, et al. Association between cytokine levels, verbal memory and hippocampus volume in psychotic disorders and healthy controls. Acta Psychiatr Scand. 2016;133:53-62.
42. Hope S, Hoseth E, Dieset I, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res. 2015;165:188-194.
43. Hamdani N, Daban-Huard C, Lajnef M, et al. Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J Affect Disord. 2015;179:161-166.
44. Hamdani N, Daban-Huard C, Lajnef M, et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 2013;148:444-448.
45. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150:456-459.
46. Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF III, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2014;29:635-644.
47. Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 2012;137:66-72.
48. Chung KH, Huang SH, Wu JY, Chen PH, Hsu JL, Tsai SY. The link between high-sensitivity C-reactive protein and orbitofrontal cortex in euthymic bipolar disorder. Neuropsychobiology. 2013;68:168-173.
49. Rolstad S, Jakobsson J, Sellgren C, et al. CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. Eur Neuropsychopharmacol. 2015;25:1091-1098.
50. Porter RJ, Robinson LJ, Malhi GS, Gallagher P. The neurocognitive profile of mood disorders - a review of the evidence and methodological issues. Bipolar Disord. 2015;17(Suppl 2):21-40.
51. Malhi GS, Byrow Y, Fritz K, et al. Mood disorders: neurocognitive models. Bipolar Disord. 2015;17(Suppl 2):3-20.
52. Baune BT, Malhi GS. A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder. Bipolar Disord. 2015;17(Suppl 2):41-55.
53. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23-34.
54. Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord. 2015;174:467-478.
55. Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 2014;129:163-179.
56. Soczynska JK, Mansur RB, Brietzke E, et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res. 2012;235:302-317.
57. Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17-32.
58. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother. 1975;8:713-720.
59. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355-366.
60. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs. 2012;26:391-401.
61. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442-1448.
62. Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337-352.
63. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini Rev Med Chem. 2012;12:44-52.
64. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:380-386.
65. Nagpal K, Singh SK, Mishra D. Evaluation of safety and efficacy of brain targeted chitosan nanoparticles of minocycline. Int J Biol Macromol. 2013;59:20-28.
66. Kreisel T, Frank MG, Licht T, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry. 2014;19:699-709.
67. Rinwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and induce antidepressent-like effect in olfactory bulbectomized rats. Neuroscience. 2013;255:86-98.
68. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry. 2009;14:511-522.
69. Henry CJ, Huang Y, Wynne A, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation. 2008;5:15.
70. Majidi J, Kosari-Nasab M, Salari AA. Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice. Brain Res Bull. 2015;120:1-13.
71. Burke NN, Kerr DM, Moriarty O, Finn DP, Roche M. Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav Immun. 2014;42:147-156.
72. Saeedi Saravi SS, Amirkhanloo R, Arefidoust A, et al. On the effect of minocycline on the depressive-like behavior of mice repeatedly exposed to malathion: interaction between nitric oxide and cholinergic system. Metab Brain Dis. 2016;31:549-561.
73. Saravi SS, Mousavi SE, Saravi SS, Dehpour AR. Minocycline attenuates depressive-like behaviour induced by rat model of testicular torsion: involvement of nitric oxide pathway. Basic Clin Pharmacol Toxicol. 2016;118:249-258.
74. Xie W, Cai L, Yu Y, et al. Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy. J Neuroinflammation. 2014;11:41.
75. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1660-1666.
76. Arakawa S, Shirayama Y, Fujita Y, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav. 2012;100:601-606.
77. Zheng X, Liang Y, Kang A, et al. Peripheral immunomodulation with ginsenoside Rg1 ameliorates neuroinflammation-induced behavioral deficits in rats. Neuroscience. 2014;256:210-222.
78. Zhu F, Zhang L, Ding YQ, Zhao J, Zheng Y. Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: implication for a new schizophrenia animal model. Brain Behav Immun. 2014;38:166-174.
79. Zhu F, Zheng Y, Ding YQ, et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS ONE. 2014;9:e93966.
80. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:336-339.
81. Liu M, Li J, Dai P, et al. Microglia activation regulates GluR1 phosphorylation in chronic unpredictable stress-induced cognitive dysfunction. Stress. 2015;18:96-106.
82. Hinwood M, Morandini J, Day TA, Walker FR. Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex. 2012;22:1442-1454.
83. Borre Y, Sir V, de Kivit S, Westphal KG, Olivier B, Oosting RS. Minocycline restores spatial but not fear memory in olfactory bulbectomized rats. Eur J Pharmacol. 2012;697:59-64.
84. Hou Y, Xie G, Liu X, et al. Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice. Psychopharmacology. 2016;233:905-916.
85. Williamson LL, Sholar PW, Mistry RS, Smith SH, Bilbo SD. Microglia and memory: modulation by early-life infection. J Neurosci. 2011;31:15511-15521.
86. Kofman O, Klein E, Newman M, et al. Inhibition by antibiotic tetracyclines of rat cortical noradrenergic adenylate cyclase and amphetamine-induced hyperactivity. Pharmacol Biochem Behav. 1990;37:417-424.
87. Kofman O, van Embden S, Alpert C, Fuchs I. Central and peripheral minocycline suppresses motor activity in rats. Pharmacol Biochem Behav. 1993;44:397-402.
88. Zhu F, Zheng Y, Liu Y, Zhang X, Zhao J. Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid. Psychiatry Res. 2014;219:680-686.
89. Zhu F, Liu Y, Zhao J, Zheng Y. Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of Granulocyte-Macrophage Colony-Stimulating Factor in adult rats. Neuroscience. 2014;266:275-281.
90. Miyaoka T, Wake R, Furuya M, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:222-226.
91. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012;26:1185-1193.
92. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014;215:540-546.
93. Liu F, Guo X, Wu R, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res. 2014;153:169-176.
94. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138-149.
95. Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015;35:374-381.
96. Oya K, Kishi T, Iwata N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2014;29:483-491.
97. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.
98. Sheehan D, Lecrubier Y, Sheehan K, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl):20.
99. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
100. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
101. Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol. 2006;16:601-611.
102. Guy W. ECDEU Assessment Manual for Psychopharmacology, 2nd edn. Rockville, MD: US Government Printing Office; 1976.
103. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
104. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
105. Lizardi H, Klein DN, Ouimette PC, Riso LP, Anderson RL, Donaldson SK. Reports of the childhood home environment in early-onset dysthymia and episodic major depression. J Abnorm Psychol. 1995;104:132-139.
106. Nelson HE, Willison JR. The Revised National Adult Reading Test-Test Manual. Windsor: NFER-Nelson; 1991.
107. Delis D, Kaplan E, Kramer J, Ber B. California Verbal Learning Test-II [Manual]. San Antonio, TX: Psychological Corporation; 2000.
108. Jacoby LL. Invariance in automatic influences of memory: toward a user's guide for the process-dissociation procedure. J Exp Psychol Learn Mem Cogn. 1998;24:3-26.
109. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System. San Antonio, TX: Harcourt Assessment, Inc; 2001.
110. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
111. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 3rd edn. New York, NY: Oxford University Press; 2006.
112. Wagner S, Helmreich I, Dahmen N, Lieb K, Tadic A. Reliability of three alternate forms of the trail making tests a and B. Arch Clin Neuropsychol. 2011;26:314-321.
113. Wechsler D. Wechsler Adult Intelligence Scale – Revised Manual. New York: Psychological Corporation; 1981.
114. Hinton-Bayre A, Geffen G. Comparability, reliability, and practice effects on alternate forms of the Digit Symbol Substitution and Symbol Digit Modalities tests. Psychol Assess. 2005;17:237-241.
115. Drane DL, Yuspeh RL, Huthwaite JS, Klingler LK. Demographic characteristics and normative observations for derived-trail making test indices. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15:39-43.
116. MacQueen GM, Galway TM, Hay J, Young LT, Joffe RT. Recollection memory deficits in patients with major depressive disorder predicted by past depressions but not current mood state or treatment status. Psychol Med. 2002;32:251-258.
117. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
118. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174-180.
119. Bilbo SD, Schwarz JM. The immune system and developmental programming of brain and behavior. Front Neuroendocrinol. 2012;33:267-286.
120. Hadamitzky M, Engler H, Schedlowski M. Learned immunosuppression: extinction, renewal, and the challenge of reconsolidation. J Neuroimmune Pharmacol. 2013;8:180-188.
121. Ader R, Cohen N. Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol. 1993;44:53-85.
122. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-alpha. Mol Psychiatry. 2016;21:642-649.
123. Post RM, Leverich GS, Altshuler LL, et al. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. Int Clin Psychopharmacol. 2011;26:96-106.
124. Klein DN, Arnow BA, Barkin JL, et al. Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depress Anxiety. 2009;26:701-710.
125. Harkness KL, Bagby RM, Kennedy SH. Childhood maltreatment and differential treatment response and recurrence in adult major depressive disorder. J Consult Clin Psychol. 2012;80:342-353.
126. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open. 2012;2:e000643.
127. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology. 2003;60:883-884.
128. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol. 2004;19:337-342.
129. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology. 2004;63:547-549.
130. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004;19:692-695.
131. Naura AS, Kim H, Ju J, et al. Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor kappaB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase. J Biol Chem. 2013;288:1458-1468.
132. Tai K, Iwasaki H, Ikegaya S, Ueda T. Minocycline modulates cytokine and chemokine production in lipopolysaccharide-stimulated THP-1 monocytic cells by inhibiting IkappaB kinase alpha/beta phosphorylation. Transl Res. 2013;161:99-109.
133. Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler. 2007;13:517-526.
134. Abdi K, Singh NJ. Making many from few: IL-12p40 as a model for the combinatorial assembly of heterodimeric cytokines. Cytokine. 2015;76:53-57.
135. Dutta K, Kumawat KL, Nazmi A, Mishra MK, Basu A. Minocycline differentially modulates viral infection and persistence in an experimental model of Japanese encephalitis. J Neuroimmune Pharmacol. 2010;5:553-565.
136. Garwood CJ, Cooper JD, Hanger DP, Noble W. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry. 2010;1:136.
137. Zychowska M, Rojewska E, Kreiner G, Nalepa I, Przewlocka B, Mika J. Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy. J Neuroimmunol. 2013;262:35-45.
138. Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7:1-19.
139. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705-716.
140. Reaux-Le GA, Van SJ, Rostene W, Melik PS. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67-92.
141. Williams JL, Holman DW, Klein RS. Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers. Front Cell Neurosci. 2014;8:154.